Using colorectal cancer cells, they were able to demonstrate that the use of WEHI-539 (a Bcl-xL inhibitor) was able to induce apoptosis, and after Bcl-xL knockdown, there was an increase in the response to irinotecan and 5-fluorouracil (5-FU). Here, BCL2L1 is linked to colorectal cancer.